What is the role of tissue factor pathway inhibitor (TFPI) in the treatment of disseminated intravascular coagulation (DIC)?

Updated: Dec 06, 2020
  • Author: Marcel M Levi, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print

The TFPI mechanism of coagulation inhibition has received attention as a potential therapy in sepsis-associated DIC. Indeed, initial results from animal studies have been very promising in demonstrating the ability of TFPI to arrest DIC and to prevent the mortality and end-organ damage witnessed in untreated animals. [90] However, a large phase III trial of TFPI in humans with DIC did not show any mortality benefit. [91]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!